AbbVie starts trading;
Abbott has completed the separation of its research-based pharmaceuticals business into AbbVie, a new independent biopharmaceutical company that starts trading today on the New York Stock Exchange.
Celgene Corp., the maker of blood cancer drugs, agreed to buy Abraxis BioScience Inc. for $2.9 billion in cash and stock to acquire a breast-tumor medicine.